



Bilirubin deficiency renders mice susceptible to hepatic steatosis in the absence of insulin resistance

Weiye Chen^{a,b}, Sergey Tumanov^{a,b}, Daniel Fazarkalev^{c,d}, James Cantley^{e,f}, David E. James^{c,g}, Louise L. Dunn^b, Taqi Shaik^a, Cacang Suarna^{a,b}, Roland Stocker^{a,b,g,*}

^a Heart Research Institute, The University of Sydney, Sydney, Australia

^b Victor Chang Cardiac Research Institute, Sydney, Australia

^c Charles Perkins Centre, School of Life and Environmental Sciences, The University of Sydney, Sydney, Australia

^d Metabolic Research Laboratory, Wellcome-Medical Research Council Institute of Metabolic Science, University of Cambridge, Cambridge, United Kingdom

^e Division of Systems Medicine, School of Medicine, University of Dundee, Dundee, United Kingdom

^f Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, United Kingdom

^g School of Life and Environmental Sciences, The University of Sydney, Sydney, Australia

ARTICLE INFO

Keywords:

Bilirubin
Insulin signaling
Lipid oxidation
F₂-isoprostanes
Vitamin E

ABSTRACT

Background & aims: Plasma concentrations of bilirubin, a product of heme catabolism formed by biliverdin reductase A (BVRA), inversely associate with the risk of metabolic diseases including hepatic steatosis and diabetes mellitus in humans. Bilirubin has antioxidant and anti-inflammatory activities and may also regulate insulin signaling and peroxisome proliferator-activated receptor alpha (PPARα) activity. However, a causal link between bilirubin and metabolic diseases remains to be established. Here, we used the global *Bvra* gene knockout (*Bvra*^{−/−}) mouse as a model of deficiency in bilirubin to assess its role in metabolic diseases.

Approach & results: We fed mice fat-rich diets to induce hepatic steatosis and insulin resistance. Bile pigments were measured by LC-MS/MS, and hepatic lipids by LC-MS/MS (non-targeted lipidomics), HPLC-UV and Oil-Red-O staining. Oxidative stress was evaluated measuring F₂-isoprostanes by GC-MS. Glucose metabolism and insulin sensitivity were verified by glucose and insulin tolerance tests, *ex vivo* and *in vivo* glucose uptake, and Western blotting for insulin signaling. Compared with wild type littermates, *Bvra*^{−/−} mice contained negligible bilirubin in plasma and liver, and they had comparable glucose metabolism and insulin sensitivity. However, *Bvra*^{−/−} mice exhibited an inflamed and fatty liver phenotype, accompanied by hepatic accumulation of oxidized triacylglycerols and F₂-isoprostanes, in association with depletion of α-tocopherol. α-Tocopherol supplementation reversed the hepatic phenotype and observed biochemical changes in *Bvra*^{−/−} mice.

Conclusions: Our data suggests that BVRA deficiency renders mice susceptible to oxidative stress-induced hepatic steatosis in the absence of insulin resistance.

1. Introduction

Non-alcoholic fatty liver disease (NAFLD) has an estimated worldwide prevalence of 25% [1] and is associated with features of metabolic syndrome that confer increased risk of cardiovascular and metabolic diseases [2,3]. NAFLD is characterized by hepatic lipid accumulation and its progression leads to hepatic steatosis (fatty liver) to non-alcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma [4,5]. The mechanisms responsible for NAFLD remain unclear, although a commonly accepted hypothesis is that the disease progresses by multiple interrelated mechanisms, including

insulin resistance, inflammation and oxidative stress [5]. It is conceivable that modifying these factors may attenuate the development and progression of NAFLD [6].

Moderate to high concentrations of plasma bilirubin, a product of biliverdin reductase A (BVRA)-dependent conversion of biliverdin generated by heme catabolism, are associated with low incidence of NAFLD [7–10], insulin resistance and type 2 diabetes [11–15], suggesting that bilirubin may protect against hepatic steatosis and metabolic diseases. This could be achieved by the pigment's inhibition of lipid oxidation alone [16,17] or via interaction with α-tocopherol (α-TOH, the most active form of vitamin E) [18]. Consistent with such antioxidant activity, we recently reported mice with very low

* Corresponding author. 7 Eliza St, Newtown, NSW, 2042, Australia.

E-mail address: roland.stocker@hri.org.au (R. Stocker).

<https://doi.org/10.1016/j.redox.2021.102152>

Received 11 August 2021; Received in revised form 26 September 2021; Accepted 26 September 2021

Available online 27 September 2021

2213-2317/© 2021 The Authors.

Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license

(<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

List of abbreviations:

BOXes	bilirubin/biliverdin oxidation
BVRA	biliverdin reductase A
<i>Bvra</i> ^{-/-} mouse	global <i>Bvra</i> gene knockout mouse
CE	cholesterylesters
DB	double bonds
GLUT4	glucose transporter type 4
GTT	glucose tolerance tests
HF	high fat diet
HFHS	high fat high sucrose diet
ITT	insulin tolerance tests
NAFLD	non-alcoholic fatty liver disease
NASH	non-alcoholic steatohepatitis
PPAR α	peroxisome proliferator-activated receptor alpha
TAG	triacylglycerides
α -TOH	α -tocopherol

concentrations of endogenous bilirubin as a result of genetic *Bvra*-deficiency (*Bvra*^{-/-}) to have elevated circulating concentrations of oxidized lipids [19]. Bilirubin also has anti-inflammatory properties ameliorating acute and chronic hepatic inflammation [20–22]. Finally, bilirubin may modulate hepatic metabolism of glucose and lipids via the glycogen synthase kinase/peroxisome proliferator-activated receptor- α and insulin receptor/PI3K/Akt signaling pathways, as suggested by experiments with liver-specific BVRA-deficient mice, in which plasma bilirubin concentrations were not shown to be regulated [23–28].

Despite these multiple lines of evidence for bilirubin and/or BVRA protecting against hepatic steatosis, the underlying mechanism remains unclear. We hypothesized that bilirubin/BVRA protect against NAFLD by decreasing oxidative stress, inflammation, and insulin resistance. To test this hypothesis, we fed global *Bvra*^{-/-} mice high fat (HF) or high fat high sucrose diet (HFHS) to induce hepatic steatosis and insulin resistance. We observed *Bvra*^{-/-} and littermate *Bvra*^{+/+} mice to have comparable fasted plasma glucose and insulin, glucose and insulin tolerance, glucose uptake, as well as insulin signaling. However, *Bvra*^{-/-} mice developed a fatty and inflamed liver associated with vitamin E depletion and increased concentrations of oxidized lipids. Administration of vitamin E reversed this phenotype and biochemical changes, indicating that bilirubin/BVRA protect mice from high fat diet-induced hepatic steatosis via antioxidant protection rather than prevention of insulin resistance.

2. Materials and methods

For extended Material and Methods, see online Supplementary materials.

2.1. Animals

biliverdin reductase a gene-deficient (*Bvra*^{-/-}) mice have been described previously [19]. *Bvra*^{+/+} and *Bvra*^{-/-} littermate male mice at 7 $\pm$ 1 weeks of age were obtained from *Bvra*^{+/+} $\times$ *Bvra*^{-/-} breeding and used for all experiments. All mice were housed in a temperature-controlled room (Physical Containment Level 2 certification) on a 12 h light/dark cycle and were allowed access to water and food *ad libitum*. All procedures were carried out according to the Australian National Health & Medical Research Council Guidelines for Animal Research and were approved by the Animal Care and Ethics Committee of the Garvan Institute of Medical Research/St Vincent's Hospital. All animals received humane care according to the criteria outlined in the "Guide for the Care and Use of Laboratory Animals."

To fully characterize the metabolic phenotype of *Bvra*^{-/-} mice

required performing multiple assays. This was achieved by using minimal group sizes for each parameter as predicted by power calculations, and by prioritizing assays that required freshly collected tissue. Group sizes for different assays varied from 5 to 18. This information is contained in Figure Legends.

2.2. Diets

Animals were maintained on a standard chow containing 13% calories from fat, 22% calories from protein, and 65% calories from carbohydrate, 3.1 kcal/g (#27, Gordons Specialty Feeds, Australia) until they were allocated to a study involving a high fat (HF) or high fat high sucrose (HFHS) diet. Where indicated, mice were fed for up to 14 weeks a HF diet formulated based on D12492 (Research Diet, Inc) containing 5.2 kcal/g with 60, 20 and 20% calories from fat, protein, and carbohydrate, respectively (SF13-092, Specialty Feeds, Australia). Alternatively, mice were fed for up to 6 weeks an in-house HFHS diet based on D12451 (Research Diets, Inc) containing 4.7 kcal/g with 47, 21 and 32% calories from fat, protein, and carbohydrate, respectively. The RRR- α -tocopheryl succinate was kindly donated by Pharma Nord, Denmark. The RRR- α -tocopheryl succinate was incorporated as powder in the HF diet obtained a concentration of RRR- α -tocopherol 0.2%, w/w in the diet.

2.3. Statistical analyses


Statistical analysis was performed using GraphPrism 8 software. Results are expressed as mean $\pm$ SEM. Normality of the data distribution was assessed (D'Agostino-Pearson test) and a Student's t-test, 1- or 2-way ANOVA, Mann-Whitney, or Kruskal-Wallis test used as appropriate. A *P*-value of <0.05 was considered as statistically significant.

3. Results

3.1. Global BVRA deficiency does not impact glucose tolerance and insulin sensitivity in mice fed standard chow

Littermate *Bvra*^{-/-} and *Bvra*^{+/+} mice fed standard chow exhibited comparable body weight (Fig. 1A), consistent with our previous observation [19]. *Bvra*^{-/-} mice had very low concentrations of hepatic bilirubin compared with *Bvra*^{+/+} littermates (0.3 $\pm$ 0.1 versus 2.9 $\pm$ 0.3 pmol/mg protein) (Fig. 1B), as determined by LC-MS/MS. Instead, biliverdin was elevated in livers of *Bvra*^{-/-} compared with *Bvra*^{+/+} mice (2.6 $\pm$ 0.1 versus 0.9 $\pm$ 0.1 pmol/mg protein) (Fig. 1C). Elevated concentrations of biliverdin were also observed in other tissues (e.g., arteries) of *Bvra*^{-/-} mice (unpublished data). However, *Bvra*^{+/+} mice had similar concentrations of biliverdin and bilirubin as in *Bvra*^{+/+} littermates [19].

There was no significant difference in non-fasted blood glucose concentrations in *Bvra*^{+/+} and *Bvra*^{-/-} littermates 7 $\pm$ 1 weeks old (Fig. 1D). Similarly, blood glucose and plasma insulin concentrations were similar in *Bvra*^{-/-} and *Bvra*^{+/+} littermates during glucose (GTT) and insulin tolerance tests (ITT) (Fig. 1E–I), indicating BVRA deficiency had no effect on glucose or insulin tolerance. Insulin resistance in adipose tissue appears early in the pathogenesis of metabolic disease [29] and can influence whole body insulin sensitivity [30,31]. Therefore, we assessed glucose uptake and insulin sensitivity in adipose tissue using [³H] 2-deoxy-D-glucose (2-DOG) and different doses of insulin. We observed no significant difference in glucose uptake between the two genotypes (Fig. 1J). Consistent with this, we observed no significant difference in the expression of glucose transporter type 4 (GLUT4), the major insulin-regulated controller of glucose uptake in adipose, between *Bvra*^{+/+} and *Bvra*^{-/-} mice (Fig. 1K). Moreover, BVRA deficiency did not affect insulin signaling in adipose explants, as indicated by the comparable extent of phosphorylation of Akt and AS160, which are key regulators of insulin-stimulated glucose uptake (Fig. 1L).



(caption on next page)

Fig. 1. Glucose tolerance, insulin sensitivity and insulin signaling are normal in *Bvra*^{-/-} mice fed standard chow. **(A)** Body weights, **(B, C)** hepatic concentrations of biliverdin and bilirubin, and **(D)** non-fasted blood glucose in *Bvra*^{+/+} and *Bvra*^{-/-} mice 7 ± 1 weeks of age. Bile pigments were measured by LC-MS/MS, with results normalized to protein content. **(E)** Blood glucose concentration following intraperitoneal glucose tolerance test (GTT, 1 g/kg glucose) in fasted (8 h) *Bvra*^{+/+} (n = 6) and *Bvra*^{-/-} (n = 5) mice, with **(F)** incremental area under the curve (iAUC). **(G)** Plasma insulin concentrations following GTT (1 g/kg glucose) in fasted (8 h) *Bvra*^{+/+} (n = 6) and *Bvra*^{-/-} mice (n = 5). **(H)** Blood glucose concentrations following insulin tolerance test (ITT, 0.75 U/kg insulin) in fasted (8 h) *Bvra*^{+/+} (n = 6) and *Bvra*^{-/-} (n = 7) mice, with **(I)** area above the curve (AAC). **(J)** Protein standardized [³H] 2-deoxy-D-glucose (2-DOG) uptake into adipose tissue explants derived from the epididymal fat pads of *Bvra*^{+/+} (n = 5) and *Bvra*^{-/-} (n = 5) mice after treatment with different concentrations of insulin. **(K)** Representative Western blot of glucose transporter type 4 (GLUT4) in adipose tissue of *Bvra*^{+/+} and *Bvra*^{-/-} mice. GLUT4 expression in adipose tissue of littermate *Bvra*^{-/-} and *Bvra*^{+/+} mice was quantified by densitometry and normalized to loading control (α-tubulin) and the expression in the *Bvra*^{+/+} group. **(L)** Representative Western blots of BVRA, Akt and AS160 phosphorylation in adipose tissue of *Bvra*^{+/+} and *Bvra*^{-/-} mice after treatment with different concentrations of insulin. Phosphorylation of Ser473 and Thr308 of Akt, and Thr642 of AS160 as assessed by densitometry, and normalized to total protein and expressed relative to *Bvra*^{+/+} mice treated with 10 nM insulin; n = 5 per genotype. Open and filled circles correspond to *Bvra*^{-/-} and *Bvra*^{+/+} mice, respectively. Numerical results show individual data as well as mean ± SEM, with data analyzed for statistical difference by the Mann-Whitney test. *P < 0.05.

3.2. BVRA deficiency does not alter high fat diet-induced glucose intolerance and insulin sensitivity

Insulin resistance, e.g., impaired tolerance to glucose and insulin, has been observed in mice on short- and long-term high fat (HF) diets [32, 33]. Therefore, we next investigated whether BVRA deficiency exacerbated glucose intolerance and insulin resistance in the setting of HF diet. Compared with our previous results from mice fed standard chow [19], HF diet had no significant effect on plasma concentrations of bile pigments in *Bvra*^{+/+} and *Bvra*^{-/-} mice (Fig. 2A&B). Similarly, body weights, fasting blood glucose concentrations, and glucose and insulin tolerance remained comparable between the two genotypes (Fig. 2C–I), as did *in vivo* insulin sensitivity in epididymal fat pads assessed by 2-DOG uptake (Fig. 2J) and phosphorylation of Akt and AS160, as well as GLUT4 expression (Fig. 2K). There was also no difference in hepatic phosphorylation of Akt and GSK3β between *Bvra*^{+/+} and *Bvra*^{-/-} mice (Fig. 2L). Finally, we examined a potential effect of BVRA deficiency on insulin sensitivity by providing *Bvra*^{+/+} and *Bvra*^{-/-} mice high fat high sucrose (HFHS) diet which, due to the addition of sucrose, induces a more pronounced glucose intolerance [29]. Again, *Bvra*^{+/+} and *Bvra*^{-/-} mice had comparable body weights, fasting blood glucose, and blood glucose and plasma insulin following injection of glucose (Supplemental Figs. 2A–E). Together, these findings suggest that global BVRA deficiency does not affect glucose metabolism and insulin sensitivity in mice, whether animals are fed standard chow, or are challenged with a HF or HFHS diet.

3.3. Deficiency of Bvra enhances HF diet-induced hepatic lipid accumulation

Chronic feeding of fat-rich diet leads to obesity-related steatosis, a manifestation of the metabolic syndrome characterized by excessive hepatic lipid accumulation [27,34]. After 14 weeks HF diet or 6 weeks HFHS diet, livers in *Bvra*^{-/-} mice showed evidence for lipid accumulation compared with control, as indicated by increased Oil Red O-positive staining and the presence of lipid droplets and vacuoles (Fig. 3A and Supplemental Fig. 2H). HPLC analysis confirmed this observation and revealed that compared with *Bvra*^{+/+} mice, livers of HF-fed *Bvra*^{-/-} mice contained more triacylglycerides (TAG, 237 ± 34 versus 551 ± 134 nmol/mg protein) and cholesterol (25 ± 3 versus 38 ± 5 nmol/mg protein) (Fig. 3B and C) but not cholesterylesters (CE) (Fig. 3D). In mice fed HFHS diet, BVRA deficiency also increased hepatic TAG (93.8 versus 70.4 nmol/mg protein), while cholesterol and CE were not different (Supplemental Figs. 2I–K). There was no significant difference in plasma cholesterol, CE and TAG between *Bvra*^{+/+} and *Bvra*^{-/-} mice fed HF diet (Supplemental Figs. 3F–H).

Development and progression of hepatic steatosis is linked to *de novo* synthesis of lipid [35]. In agreement with enhanced lipid accumulation in *Bvra*^{-/-} mice fed HF diet, mRNA of enzymes involved in lipid synthesis, i.e., acetyl-CoA carboxylase (*Acaca*) and fatty acid synthase (*Fasn*), but not sterol regulatory element-binding transcription factor 1 (*Srebf1*), were increased compared with *Bvra*^{+/+} littermates (Fig. 3E–G).

Liver weights, liver-to-bodyweight ratios, and plasma ALT activities (Fig. 3H–J) were comparable in *Bvra*^{-/-} and *Bvra*^{+/+} mice. As excess fat can cause chronic inflammation, we determined F4/80 expression as a marker of Kupffer cells. Compared with *Bvra*^{+/+} mice fed HF diet, *Bvra*^{-/-} mice had increased F4/80 (Fig. 3K) and mRNA of the pro-inflammatory cytokines MCP-1 and TNF-α, while mRNA of interleukins-1β, -6 and -10 remained similar (Fig. 3L).


The above results suggest that *Bvra* deficiency in combination with a HF diet enhances hepatic fat accumulation and inflammation. Fatty liver can progress to hepatic fibrosis. However, we observed only mild fibrosis, as assessed by Fast green Sirius red staining, in the liver *Bvra*^{+/+} or *Bvra*^{-/-} mice fed HF diet, and no significant difference was observed between the genotypes (Supplementary Fig. 4).

3.4. Bvra deficiency moderately regulates PPARα activity

Stec and co-workers reported liver-specific BVRA deficiency caused hepatic steatosis via a decrease peroxisome proliferator-activated receptor-α (PPARα) activity and resulting attenuated hepatic lipid metabolism [27]. Hepatic concentrations of bilirubin and biliverdin in mice with liver specific BVRA deficiency were not reported, which may be important as biliverdin has been shown to activate PPARα more efficiently than bilirubin in a cellular reporter system [25]. We therefore first determined hepatic concentrations of bile pigments in *Bvra*^{-/-} and *Bvra*^{+/+} mice fed a HF diet using LC-MS/MS. Global BVRA deficiency significantly decreased hepatic bilirubin, and this was associated with a commensurate increase in biliverdin, such that total bile pigment concentrations were comparable in the two genotypes (Fig. 4A–C). Consistent with this, we observed only a modest (~30%) increase in PPARα phosphorylation, a marker of decreased PPARα expression [27], in *Bvra*^{-/-} compared with *Bvra*^{+/+} mice as assessed by Western blotting, while PPARα protein expression was not different (Fig. 4D). This increase in PPARα phosphorylation was associated with a small albeit significant decrease in mRNA levels of some (carnitine palmitoyl-transferase 1A, *Cpt1a*; cytochrome P450, family 2 (*Cyp2j6*) and 4, (*Cyp4a12j*), but not other PPARα-targeted genes (cluster of differentiation 36, *Cd36*; glucose 6-phosphatase, *G6pase*) (Fig. 4E). Together, these results indicate that global BVRA deficiency at most decreases hepatic PPARα activity modestly, and that other factors need to be considered to explain the observed steatosis in *Bvra*^{-/-} mice.

3.5. Bvra deficiency increases hepatic lipid oxidation associated with a decrease in α-tocopherol

We next considered non-enzymatic lipid oxidation as an alternative cause of hepatic lipid accumulation in *Bvra*^{-/-} mice [36], as biliverdin protects lipids more effectively from non-enzymatic oxidation than bilirubin [16], and circulating lipids are more oxidized in *Bvra*^{-/-} than *Bvra*^{+/+} mice [19]. Non-targeted lipidomic analysis of livers from *Bvra*^{+/+} and *Bvra*^{-/-} mice fed HF diet identified 781 lipid species, with the top 50 regulated lipids presented as a heatmap (Fig. 5A). As can be seen, livers of *Bvra*^{-/-} mice contained significantly more TAG (Fig. 5B),



(caption on next page)

Fig. 2. *Bvra* deficiency does not aggravate glucose intolerance, insulin resistance and insulin signaling in mice fed high fat (HF) diet. (A, B) Plasma biliverdin and bilirubin in *Bvra*^{+/+} and *Bvra*^{-/-} mice fed HF diet for 12 weeks. (C) Weekly body weights of *Bvra*^{+/+} and *Bvra*^{-/-} mice fed a HF diet over 12 weeks (*n* = 12 per genotype). (D) Blood glucose concentrations in fasted (8 h) *Bvra*^{+/+} (*n* = 11) and *Bvra*^{-/-} mice (*n* = 11) fed HF diet for 5, 28, 56 and 84 days. (E) Blood glucose concentrations following GTT (1 g/kg glucose) in fasted (8 h) *Bvra*^{+/+} (*n* = 11) and *Bvra*^{-/-} mice (*n* = 11) fed HF diet for 12 weeks, with (F) iAUC for GTT performed after HF diet for 5, 28, 56 and 84 days. (G) Plasma insulin concentrations following GTT (1 g/kg glucose) in fasted (8 h) *Bvra*^{+/+} (*n* = 11) and *Bvra*^{-/-} mice (*n* = 11) fed HF diet for 84 days. (H) Blood glucose concentrations following ITT (0.75 U/kg insulin) in fasted (8 h) *Bvra*^{+/+} (*n* = 6) and *Bvra*^{-/-} (*n* = 7) mice fed HF diet for 12 weeks, with (I) AAC for blood glucose concentrations following ITT performed after HF diet for 5, 28, 56 and 84 days. (J) Insulin-induced 2-DOG uptake into epididymal adipose tissue of *Bvra*^{+/+} and *Bvra*^{-/-} mice fed HF diet for 14 weeks. Data was normalized to tissue weight. (K) Representative Western blots of BVRA, GLUT4, and phosphorylated Akt and AS160 in epididymal adipose tissue of *Bvra*^{+/+} and *Bvra*^{-/-} mice fed HF diet for 14 weeks (two independent experiments). Densitometry analysis of expression of GLUT4, phosphorylation of Ser473 and Thr308 of Akt, and Thr642 of AS160 in adipose tissue of *Bvra*^{+/+} (*n* = 12) and *Bvra*^{-/-} (*n* = 11) mice. Data was normalized to total protein content or loading control (14-3-3) respectively. (L) Western blots of BVRA, phosphorylated Akt and GSK3 β in liver of *Bvra*^{+/+} and *Bvra*^{-/-} mice fed HF diet for 14 weeks (two independent experiments). (M) Densitometry analysis of phosphorylated Ser473 and Thr308 of Akt, and Ser9 of GSK3 β in liver of *Bvra*^{+/+} (*n* = 12, filled circles) and *Bvra*^{-/-} (*n* = 11, open circles) mice. Numerical results show individual data as well as mean $\pm$ SEM, with data analyzed for statistical difference by the Mann-Whitney test. **P* < 0.05.

confirming the HPLC-UV data. Compared with livers from *Bvra*^{+/+} littermates, *Bvra*^{-/-} mice had significantly elevated concentrations of oxidized TAG (oxTAG) (Fig. 5C), as well as increased ratios of oxTAG to total TAG (Fig. 5D). We also expressed oxTAG per TAG with more than three double bonds (DB > 3), reasoning that TAG_{DB>3} contain at least one fatty acid with an isolated double bond and associated pair of bisallylic hydrogens that render lipids susceptible to oxidation. The ratios of oxTAG to TAG_{DB>3} was significantly increased in livers of *Bvra*^{-/-} than *Bvra*^{+/+} mice despite comparable TAG_{DB>3} (Fig. 5E and F). Similarly, the ratio of oxidized PC (oxPC) to PC_{DB>2} was significantly increased in livers of *Bvra*^{-/-} compared with *Bvra*^{+/+} mice despite comparable concentrations of PC and PC_{DB>2} (Supplemental Fig. 3).

To separately probe the implied presence of oxidative stress in livers of *Bvra*^{-/-} mice, we determined liver concentrations of α -tocopherol (α -TOH), the most abundant lipid-soluble antioxidant in mammals that protects lipids with bisallylic hydrogens from non-enzymatic oxidation. Compared with *Bvra*^{+/+} littermates, *Bvra*^{-/-} mice had decreased ratios of α -TOH to TAG_{DB>3} (Fig. 5G), indicating decreased antioxidant protection of lipids. Interestingly, hepatic concentrations of ascorbic acid, a water-soluble antioxidant able to maintain α -TOH in the antioxidant active form [37], were not different between *Bvra*^{+/+} and *Bvra*^{-/-} mice (Fig. 5H). We also assessed the extent of bile pigment oxidation by determining their end products, or BOXes, by LC-MS/MS [38,39]. The ratio of hepatic BOXes to TAG_{DB>3} was significantly decreased in *Bvra*^{-/-} compared with *Bvra*^{+/+} mice (Fig. 5I), indicating that BVRA deficiency decreased the combined antioxidant protection provided by biliverdin and bilirubin.

3.6. α -Tocopherol prevents hepatic lipid oxidation and lipid accumulation in *Bvra*^{-/-} mice

The above results suggest that non-enzymatic lipid oxidation, resulting from decreased endogenous lipid-soluble antioxidants (bilirubin and α -TOH), may cause hepatic lipid accumulation in *Bvra*^{-/-} mice. As bilirubin cannot be administered readily to animals, we therefore tested whether α -TOH supplements reverses hepatic lipid oxidation and steatosis in BVRA deficiency by feeding *Bvra*^{+/+} and *Bvra*^{-/-} mice a HF diet $\pm$ α -TOH (0.2%, w/w, RRR- α -TOH, the most active form of vitamin E) for 14 weeks. Supplementation with α -TOH had no effect on body weights (Fig. 6A), although it increased hepatic α -TOH concentrations in *Bvra*^{-/-} mice (Fig. 6B). This was associated with a decrease in oxTAG and the ratios of oxTAG-to-total TAG and oxTAG-to-TAG_{DB>3} (Fig. 6E–G). More importantly, α -TOH supplementation restored wild-type hepatic concentrations of TAG (Fig. 6D) and it prevented both the fatty liver and inflammatory phenotype in *Bvra*^{-/-} mice, as assessed by Oil Red O staining (Fig. 6C) and F4/80 expression, respectively (Fig. 6J).

As bilirubin and α -TOH inhibit non-enzymatic lipid oxidation and supplementation with α -TOH prevents such lipid oxidation and reverses the fatty liver phenotype, we next asked whether oxidative stress and associated non-enzymatic lipid oxidation causes the fatty liver


phenotype in *Bvra*^{-/-} mice fed HF diet. To do so, we used gas chromatography mass spectrometry to determine hepatic concentrations of F₂-IsoP, a specific product of non-enzymatic lipid oxidation regarded as the gold standard biomarker of *in vivo* oxidative stress. Compared with the corresponding wild-type control, livers of *Bvra*^{-/-} mice had increased concentration of F₂-IsoP, and α -TOH supplementation restored wild type concentrations of F₂-IsoP (Fig. 6H). In contrast, hepatic concentrations of enzymatic lipid oxidation products were comparable in *Bvra*^{+/+} and *Bvra*^{-/-} littermate mice fed a HF diet, with or without α -TOH supplementation (Fig. 6I), as assessed by Ion Mobility Quadrupole Time-of-Flight mass spectrometry. Together, these results indicate that BVRA deficiency increases non-enzymatic lipid oxidation in the liver and that this, rather than enzymatic lipid oxidation, is a driver of both hepatic inflammation and formation of a fatty liver.

4. Discussion

This study shows that *Bvra*^{-/-} mice lack bilirubin in the liver, and that they respond to high fat diets comparably to wildtype littermate animals with regards to glucose metabolism and insulin sensitivity. Despite this, *Bvra*^{-/-} mice challenged with high fat diets develop a fatty and inflamed liver driven by increased non-enzymatic lipid oxidation and depletion of α -TOH, as restoration of hepatic α -TOH prevented such lipid oxidation, inflammation and steatosis. Together, the results indicate that protection from NAFLD observed in individuals with moderately to highly elevated bilirubin [7–10] may be due to an antioxidant action by the bile pigment in the liver.

Evidence for the presence of steatosis in *Bvra* deficiency combined with a high fat diet (HF or HFHS) is based on histological (Red-O staining) and analytical evidence, the latter including both targeted (HPLC-UV) and non-targeted (LC-MS/MS) analyses. This revealed the presence of lipid droplets and elevated concentrations of TAG. In agreement with these finding, livers of *Bvra*^{-/-} mice had increased expression of *Acaca* and *Fasn* that encode key enzymes in *de novo* lipogenesis. Moreover, catabolism of fatty acids appeared decreased, as mRNA of *Cpt1a* (an essential factor to trigger mitochondrial β -oxidation of long chain fatty acids) and *Cyp2j6* and *Cyp4a12* (catalysing the first step in ω -oxidation of fatty acids) [40] were decreased in *Bvra*^{-/-} mice. In contrast, hepatic mRNA expression of *Cd36* was not affected by BVRA deficiency, indicating that enhanced fatty acid esterification leading to TAG lipid droplets was likely taking place in the extracellular space [41]. Also, as plasma lipid concentrations were unaffected in *Bvra*^{-/-} mice fed high fat diets, indicating that the observed steatosis was most likely caused by local changes in lipid metabolism. Accordingly, lipid peroxidation may exacerbate mitochondrial dysfunction, thereby promoting lipid accumulation because of decreased β -oxidation/lipid metabolism [6].

In parallel to the observed hepatic lipid accumulation, *Bvra* deficiency also increased hepatic inflammation, as indicated by the increase in F4/80 staining. As F4/80 is a macrophage marker, these results suggest that enhanced inflammation was likely due to the increase in






Fig. 4. *Bvra* and bilirubin deficiency modestly regulates hepatic PPAR α activity in mice fed HF diet. (A, B, C) Hepatic concentration of biliverdin, bilirubin and total bile pigments in *Bvra*^{+/+} and *Bvra*^{-/-} mice determined by LC-MS/MS with results normalized to protein. (D) Representative Western blots of PPAR α phosphorylation in liver of *Bvra*^{+/+} and *Bvra*^{-/-} mice fed HF diet for 14 weeks. Densitometry analysis of expression of hepatic PPAR α and phosphorylation of Ser73. Data was normalized to total protein content or loading control (Actin). (E) Semi-quantitative RT-PCR of *Cpt1a*, *Cyp2j6*, *Cyp4a12*, *Cd36*, *G6pase* mRNA transcripts in liver of *Bvra*^{+/+} ($n = 13$, filled circles) and *Bvra*^{-/-} mice ($n = 11$, open circles) fed HF diet for 14 weeks. Open and filled circles correspond to *Bvra*^{-/-} and *Bvra*^{+/+} mice respectively. Results shown are expressed as mean $\pm$ SEM, with data analyzed for statistical difference by the Mann-Whitney test. * $P < 0.05$.

Kupffer cells. If so, this could explain the concomitant increase in the expression of inflammatory cytokines TNF α and MCP-1 that potentially exacerbate hepatic inflammation via cross talk with hepatocytes.

We are not aware of previous studies reporting the presence of biliverdin in liver of wildtype mice or other mammals, whereas we observed ~25% of hepatic bile pigments to be present as biliverdin in livers of *Bvra*^{+/+} mice, independent of the diet used. This is different to the situation in plasma, where biliverdin accounts for only ~1% of bile pigments. In fact, biliverdin is commonly thought to be essentially undetectable *in vivo* [42] due to the kinetic efficiency of BVRA. Bile pigments were detected by an LC-MS/MS-based method, providing high analytical specificity. The presence of biliverdin in the liver of C57BL/6J mice fed standard chow or high fat diet indicates that available BVRA activity is insufficient to ‘deal with’ the amounts of biliverdin formed. Our data also suggests a potential limitation to the perceived role of BVRA in ‘releasing’ biliverdin from heme oxygenase to ‘accelerate’ the rate-limiting step in heme degradation by the oxygenase [43]. In any case, our findings warrant further investigation into the potential

biological activities of biliverdin in the liver.

We provide direct evidence that *Bvra* deficiency increases oxidative stress and that this results in the oxidation of hepatic lipids. Evidence for the presence of oxidative stress comes from both, the observed decrease in hepatic concentrations of α -TOH and the increase in F₂-IsoP, the latter regarded as the gold standard biomarker of *in vivo* oxidative stress [44]. Non-targeted lipidomics and ion mobility LC-MS analyses revealed that the inflammatory hepatic steatosis in the *Bvra*^{-/-} mice was accompanied by an increase in enzymatically oxidized fatty acids in the form of oxTAG and oxPC. As expected, the concentration of these enzymatic lipid oxidation products was unaffected by α -TOH supplementation, and therefore not likely responsible for the observed steatosis in BVRA deficiency.

In contrast to enzymatic lipid oxidation, BVRA deficiency increased, and α -TOH supplementation decreased, the hepatic concentration of the non-enzymatic lipid oxidation products F₂-IsoP. This suggests non-enzymatic lipid oxidation as a cause for the observed inflammatory steatosis in *Bvra*^{-/-} mice. In support of this interpretation, *in vivo*




Fig. 5. *Bvra* deficiency depletes hepatic α -tocopherol (α -TOH) and increases lipid oxidation in mice fed HF diet. **(A)** Untargeted lipidomic analysis of livers from *Bvra*^{+/+} and *Bvra*^{-/-} mice. **(B–F)** Concentrations of hepatic total TAG, oxidized TAG (oxTAG), ratio of oxTAG-to-total TAG, ratio of TAG containing fatty acids with more than three double bonds (TAG_{DB>3}) to total TAG, and oxTAG-to-TAG_{DB>3} ratio in *Bvra*^{+/+} and *Bvra*^{-/-} mice. Lipids were determined by LC-MS/MS and their concentrations assessed by area comparison of individual lipid signals with that of the corresponding internal lipid standard. **(G)** Ratio of hepatic α -TOH-to-TAG and α -TOH-to-TAG_{DB>3} in *Bvra*^{+/+} and *Bvra*^{-/-} mice. **(H)** Hepatic ascorbate in *Bvra*^{+/+} and *Bvra*^{-/-} mice determined by HPLC. **(I)** Ratio of oxidation products of bile pigments (BOXes)-to-TAG_{DB>3} and BOXes -to-bile pigments in liver of *Bvra*^{+/+} and *Bvra*^{-/-} mice. Results of hepatic TAG and oxTAG were normalized to tissue weight (mg), while ascorbate was normalized to protein. Results shown are mean $\pm$ SEM with data analyzed for statistical difference using the Mann-Whitney test. **P* < 0.05.




Fig. 6. α -Tocopherol prevents hepatic lipid accumulation and lipid oxidation in *Bvra*^{-/-} mice fed HF diet for 14 weeks. **(A)** Body weights of *Bvra*^{+/+} and *Bvra*^{-/-} mice fed a HF diet $\pm$ α -TOH supplement (0.2% RRR- α -TOH, w/w). **(B)** Ratio of hepatic α -TOH-to-TAG and α -TOH-to-TAG_{DB>3} in *Bvra*^{+/+} and *Bvra*^{-/-} mice fed HF diet $\pm$ α -TOH. α -TOH was measured by LC-MS/MS and results normalized to tissue weight (mg). **(C)** Representative H&E and Oil Red O-stained liver sections of *Bvra*^{+/+} and *Bvra*^{-/-} mice fed HF $\pm$ α -TOH. Scale bar = 100 μ m, with quantification also provided. **(D–G)** Concentrations of hepatic total TAG, oxTAG, oxTAG-to-total TAG, and oxTAG-to-TAG_{DB>3} in *Bvra*^{+/+} and *Bvra*^{-/-} mice fed HF $\pm$ α -TOH. **(H)** Hepatic F₂-IsoP in *Bvra*^{+/+} and *Bvra*^{-/-} mice fed HF diet $\pm$ α -TOH. **(I)** Enzymatic lipid oxidation products in the liver of *Bvra*^{+/+} and *Bvra*^{-/-} mice fed HF diet $\pm$ α -TOH. TAG and oxTAG were measured by untargeted lipidomic analysis using LC-MS/MS, F₂-IsoP were measured by GC-MS and enzymatic lipid oxidation products by ion mobility Q-TOF LC/MS. **(J)** IHC of F4/80 and rat IgG isotype control in liver sections of *Bvra*^{+/+} and *Bvra*^{-/-} mice fed HF diet $\pm$ α -TOH, with corresponding quantitative data of F4/80 positive area. Scale bar = 100 μ m. Numerical results show individual data as well as mean $\pm$ SEM, with data analyzed for statistical difference using the Kruskal Wallis test. **P* < 0.05. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)

administration of a free radical generator has been reported to cause non-enzymatic lipid oxidation and a fatty liver in mice [36]. Oxidative stress has also been implicated in the pathogenesis of NAFLD [6]. If oxidative stress and resulting non-enzymatic lipid oxidation is causally involved in the development of NAFLD, supplementation of lipid-soluble radical scavenging antioxidants should be effective in suppressing the disease. We addressed this question by supplementing *Bvra*^{-/-} mice fed high fat diet with RRR- α -TOH. This not only inhibited non-enzymatic lipid oxidation but also reversed hepatic steatosis and inflammation. Our findings may have translational implications, because supplementation of humans with 800 IU/day α -TOH has been reported to inhibit the total NAFLD activity score in non-diabetic adults with nonalcoholic steatohepatitis [45]. A recent practice guidance for the diagnosis and management of NAFLD by the American Association for the Study of Liver Diseases [46] stated “Vitamin E (RRR α -tocopherol) administered at a daily dose of 800 IU/day improves liver histology in nondiabetic adults with biopsy-proven NASH and therefore may be considered for this patient population. Risks and benefits should be discussed with each patient before starting therapy. Until further data supporting its effectiveness become available, vitamin E is not recommended to treat NASH in diabetic patients, NAFLD without liver biopsy, NASH cirrhosis, or cryptogenic cirrhosis”.

The present study used BVRA-deficient mice as a model of bilirubin deficiency. A limitation of this model is that it does not allow to immediately assign any observed phenotype to either the absence of BVRA or bilirubin, or both. Previous studies suggested that in addition to catalysing the reduction of biliverdin to bilirubin, BVRA may also regulate glucose metabolism and insulin signaling [24,28,47,48]. Stec and co-workers reported hepatic steatosis and impaired hepatic insulin signaling in liver-specific BVRA knockout mice fed the same high fat diet for the same duration as in the present work [27]. They also reported BVRA and its enzymatic product bilirubin to attenuate hepatic steatosis via the activation of PPAR α signaling pathway to promote β -oxidation of fatty acids [25–27]. We also observed global BVRA deficiency to indirectly decrease β -oxidation. However, any effect on the PPAR α signaling pathway was modest, and *Bvra*^{-/-} mice fed a high fat diet had comparable insulin sensitivity and signaling compared to littermate control animals, as assessed by multiple parameters, and using two different types of high fat diets. Others reported a deficiency in PPAR α to not alter insulin sensitivity in mice maintained on high fat diet, as assessed by hyperinsulinemic-euglycemic clamp studies [49]. These results indicate potential differences between the two mouse models and suggest that the resulting phenotypic differences may be explained by differences in hepatic bilirubin concentrations and/or the fact that BVRA can activate or inhibit glucose uptake and insulin signaling [48]. Further studies are required to establish a role for BVRA in *in vivo* glucose metabolism and insulin sensitivity.

Hepatic steatosis is widely believed to result in insulin resistance [4, 50]. However, there is also evidence indicating that hepatic lipid accumulation is insufficient to cause, and can occur independent of, insulin resistance [51,52], especially hepatic insulin resistance [53]. Intrahepatic accumulation of TAG may be more a marker than cause of insulin resistance, as exemplified by patients with familial hypobetalipoproteinemia in whom hepatic steatosis is dissociated from insulin resistance [54].

Bilirubin is a potent non-enzymatic antioxidant in its own right for both the lipid and aqueous phase [16], and the pigment can also afford effective inhibition of lipid oxidation through interaction with α -TOH [18]. Therefore, it is tempting to speculate that the observed increase in non-enzymatic lipid oxidation in the liver of *Bvra*^{-/-} mice was due to their lack of bilirubin rather than the absence of BVRA. Consistent with this interpretation, we reported previously that lipid oxidation products are increased in blood plasma of *Bvra*^{-/-} compared with *Bvra*^{+/+} mice fed standard chow [19]. Also, our observation that products of bilirubin/biliverdin oxidation (BOXes) are present in livers of *Bvra*^{+/+} mice fed high fat diet directly shows that hepatic bilirubin acts as an

antioxidant *in vivo*. Interestingly, we detected biliverdin in the livers of both *Bvra*^{+/+} and *Bvra*^{-/-} mice. As biliverdin also has antioxidant activity [16], and its liver concentrations were higher in *Bvra*^{-/-} than wildtype mice, it is conceivable that biliverdin may compensate for bilirubin as a non-enzymatic antioxidant. Inconsistent with this idea, however, hepatic concentrations of α -TOH and BOXes were lower and non-enzymatic lipid oxidation products were higher in livers of *Bvra*^{-/-} compared with *Bvra*^{+/+} mice. Also, *in vitro* biliverdin has lower antioxidant activity than bilirubin [16]. Surprisingly, we observed no change in hepatic ascorbate between *Bvra*^{-/-} and *Bvra*^{+/+} mice. In contrast to bilirubin, ascorbate requires α -TOH to protect lipids from oxidation, so that the depletion of hepatic α -TOH in *Bvra*^{-/-} mice may explain why tissue concentrations of ascorbate were unaffected and substantial non-enzymatic lipid oxidation, especially within large lipid droplets, took place despite the presence of normal concentrations of ascorbate. A prerequisite for this may be that lipid oxidation is initiated within the ‘lipid phase’, by a presently unknown cause.

The almost complete systemic absence of bilirubin makes *Bvra*^{-/-} mice a useful tool to address the physiological roles of bilirubin, especially as provision of exogenous bilirubin is not a feasible approach due to the pigment’s effective insolubility in physiological buffers. By comparison, there is currently no evidence that tissue-specific BVRA knock-out affects bilirubin concentrations systemically or locally, so that this approach is not suitable to directly assess the biological roles of bilirubin. A complicating factor of *Bvra*^{-/-} mice is that they have elevated concentrations of biliverdin in plasma, bile, and other tissues, including liver and arteries (unpublished data), and the physiological roles of biliverdin in mammals are not well understood. Pharmacological induction of hyperbilirubinemia by atazanavir (that inhibits bilirubin conjugation), has been reported to protect against metabolic and cardiovascular diseases in HIV patients [55,56]. Therefore, pharmacological tools may be useful in unravelling the mechanisms underlying the protective effects of bilirubin, as well as in its translation as novel strategies for the treatment of cardiovascular and metabolic diseases. Although *Bvra* mRNA and BVRA protein are completely absent in *Bvra*^{-/-} mice, very low concentrations of bilirubin were detected in the liver, plasma, and other tissues, consistent with our previous observation [19]. The residual bilirubin detected in *Bvra*^{-/-} mice may be due to biliverdin reductase B (BVRB), which is present in mammals and can also reduce biliverdin to bilirubin.

In conclusion, our findings for the first time, support the hypothesis proposed nearly 35 years ago [16] that bilirubin has a biological function by acting as a physiological antioxidant. Our metabolic characterization of *Bvra*^{-/-} mice indicates that the inflammatory steatosis is caused by the local depletion of the lipid-soluble antioxidants α -TOH and bilirubin, and its associated non-enzymatic lipid oxidation. As high concentrations of supplemented α -TOH may increase the risk of all-cause mortality [57,58], prostate cancer [59], and hemorrhagic stroke [60], elevating the endogenous antioxidant bilirubin deserves consideration as a potential alternative treatment in the management of NAFLD in patients where conventional management fails.

Future investigations will utilize the *Bvra* deficient mouse line to establish a potential causative link between bilirubin and protection against cardiovascular disease, as increased plasma bilirubin is also inversely associated to low risk of cardiovascular disease.

Author contributions

WC and RS designed the studies and drafted the manuscript. WC characterized the metabolic phenotype in *Bvra*^{-/-} mice. LD assisted GTT, ITT, histology, and molecular biology. DF, JC, and DJ assisted with the HF and HFHS studies, and initial glucose uptake and insulin signaling studies. CS and RS designed and assisted with the HPLC analysis of lipids. CS helped with the LC-MS/MS analysis of bile pigments. ST carried out lipidomic analysis. ST and TS carried GC-MS analysis of F₂-isoprostanes. All authors read and approved the manuscript.

Declaration of competing interest

None declared.

Acknowledgments

We thank Darren Newington, Kristen Cooke, and Ciana Diskin for technical assistance, Drs Julian Griffin and Sonia Liggi (Imperial College, London) for generously providing their Ion Mobility mass spectrometry library of enzymatically oxidized fatty acids, and Dr Stefan Ryter for providing constructive critique on the manuscript. This work was supported by National Health & Medical Research Council Program Grant 1052616 and Senior Principal Research Fellowship 1111632 to RS. WC acknowledges support received in form of a University of New South Wales International Postgraduate Award. We thank New South Wales Government Office for Health and Medical Research for infrastructure support.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.redox.2021.102152>.

Financial support statement

This work was supported by National Health & Medical Research Council of Australia Program Grant 1052616 and Senior Principal Research Fellowship 1111632 to RS. WC acknowledges support received in form of a University of New South Wales International Postgraduate Award.

References

- [1] Z.M. Younossi, A.B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, M. Wymer, Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes, *Hepatology* 64 (2016) 73–84.
- [2] P. Perrone-Filardi, S. Paolillo, P. Costanzo, G. Savarese, B. Trimarco, R.O. Bonow, The role of metabolic syndrome in heart failure, *Eur. Heart J.* 36 (2015) 2630–2634.
- [3] B. Bozkurt, D. Aguilar, A. Deswal, S.B. Dunbar, G.S. Francis, T. Horwich, M. Jessup, et al., Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association, *Circulation* 134 (2016) e535–e578.
- [4] G. Marchesini, E. Bugianesi, G. Forlani, F. Cerrelli, M. Lenzi, R. Manini, S. Natale, et al., Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome, *Hepatology* 37 (2003) 917–923.
- [5] H. Tilg, A.R. Moschen, Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis, *Hepatology* 52 (2010) 1836–1846.
- [6] Z. Chen, R. Tian, Z. She, J. Cai, H. Li, Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease, *Free Radic. Biol. Med.* 152 (2020) 116–141.
- [7] R. Kumar, A. Rastogi, J.S. Maras, S.K. Sarin, Unconjugated hyperbilirubinemia in patients with non-alcoholic fatty liver disease: a favorable endogenous response, *Clin. Biochem.* 45 (2012) 272–274.
- [8] M.S. Kwak, D. Kim, G.E. Chung, S.J. Kang, M.J. Park, Y.J. Kim, J.H. Yoon, et al., Serum bilirubin levels are inversely associated with nonalcoholic fatty liver disease, *Clin. Mol. Hepatol.* 18 (2012) 383–390.
- [9] Y.C. Lin, P.F. Chang, F.C. Hu, M.H. Chang, Y.H. Ni, Variants in the UGT1A1 gene and the risk of pediatric nonalcoholic fatty liver disease, *Pediatrics* 124 (2009) e1221–e1227.
- [10] K. Puri, V. Nobili, K. Melville, C.D. Corte, M.R. Sartorelli, R. Lopez, A.E. Feldstein, et al., Serum bilirubin level is inversely associated with nonalcoholic steatohepatitis in children, *J. Pediatr. Gastroenterol. Nutr.* 57 (2013) 114–118.
- [11] P. Cheriyath, V.S. Gorrepati, I. Peters, V. Nookala, M.E. Murphy, N. Srouji, D. Fischman, High total bilirubin as a protective factor for diabetes mellitus: an analysis of NHANES data from 1999–2006, *J. Clin. Med. Res.* 2 (2010) 201–206.
- [12] L.Y. Lin, H.K. Kuo, J.J. Hwang, L.P. Lai, F.T. Chiang, C.D. Tseng, J.L. Lin, Serum bilirubin is inversely associated with insulin resistance and metabolic syndrome among children and adolescents, *Atherosclerosis* 203 (2009) 563–568.
- [13] Y. Wu, M. Li, M. Xu, Y. Bi, X. Li, Y. Chen, G. Ning, et al., Low serum total bilirubin concentrations are associated with increased prevalence of metabolic syndrome in Chinese, *J. Diabetes* 3 (2011) 217–224.
- [14] K.M. Kwon, J.H. Kam, M.Y. Kim, M.Y. Kim, C.H. Chung, J.K. Kim, J.A. Linton, et al., Inverse association between total bilirubin and metabolic syndrome in rural Korean women, *J. Womens Health (Larchmt)* 20 (2011) 963–969.
- [15] S.H. Choi, K.E. Yun, H.J. Choi, Relationships between serum total bilirubin levels and metabolic syndrome in Korean adults, *Nutr. Metabol. Cardiovasc. Dis.* 23 (2013) 31–37.
- [16] R. Stocker, Y. Yamamoto, A.F. McDonagh, A.N. Glazer, B.N. Ames, Bilirubin is an antioxidant of possible physiological importance, *Science* 235 (1987) 1043–1046.
- [17] R. Stocker, A.N. Glazer, B.N. Ames, Antioxidant activity of albumin bound bilirubin, *Proc. Natl. Acad. Sci. U.S.A.* 84 (1987) 5918–5922.
- [18] J. Neuzil, R. Stocker, Free and albumin-bound bilirubin is an efficient co-antioxidant for α -tocopherol, inhibiting plasma and low density lipoprotein lipid peroxidation, *J. Biol. Chem.* 269 (1994) 16712–16719.
- [19] W. Chen, G.J. Maghazal, A. Ayer, C. Suarna, L.L. Dunn, R. Stocker, Absence of the biliverdin reductase-a gene is associated with increased endogenous oxidative stress, *Free Radic. Biol. Med.* 115 (2018) 156–165.
- [20] W.W. Wang, D.L. Smith, S.D. Zucker, Bilirubin inhibits iNOS expression and NO production in response to endotoxin in rats, *Hepatology* 40 (2004) 424–433.
- [21] S. Hayashi, R. Takamiya, T. Yamaguchi, K. Matsumoto, S.J. Tojo, T. Tamatani, M. Kitajima, et al., Induction of heme oxygenase-1 suppresses venular leukocyte adhesion elicited by oxidative stress: role of bilirubin generated by the enzyme, *Circ. Res.* 85 (1999) 663–671.
- [22] H. Dong, H. Huang, X. Yun, D.S. Kim, Y. Yue, H. Wu, A. Sutter, et al., Bilirubin increases insulin sensitivity in leptin-receptor deficient and diet-induced obese mice through suppression of ER stress and chronic inflammation, *Endocrinology* 155 (2014) 818–828.
- [23] L. O'Brien, P.A. Hosick, K. John, D.E. Stec, T.D. Hinds Jr., Biliverdin reductase isozymes in metabolism, *Trends Endocrinol. Metabol.* 26 (2015) 212–220.
- [24] M.D. Maines, Potential application of biliverdin reductase and its fragments to modulate insulin/IGF-1/MAPK/PI3-K signaling pathways in therapeutic settings, *Curr. Drug Targets* 11 (2010) 1586–1594.
- [25] D.E. Stec, K. John, C.J. Trabbic, A. Luniwal, M.W. Hankins, J. Baum, T.D. Hinds Jr., Bilirubin binding to PPAR α inhibits lipid accumulation, *PloS One* 11 (2016), e0153427.
- [26] T.D. Hinds Jr., P.A. Hosick, S. Chen, R.H. Tukey, M.W. Hankins, A. Nestor-Kalinowski, D.E. Stec, Mice with hyperbilirubinemia due to Gilbert's syndrome polymorphism are resistant to hepatic steatosis by decreased serine 73 phosphorylation of PPAR α , *Am. J. Physiol. Endocrinol. Metab.* 312 (2017) E244–E252.
- [27] T.D. Hinds Jr., K.A. Burns, P.A. Hosick, L. McBeth, A. Nestor-Kalinowski, H. A. Drummond, A.A. AlAmadi, et al., Biliverdin reductase A attenuates hepatic steatosis by inhibition of glycogen synthase kinase (GSK)3 β phosphorylation of serine 73 of peroxisome proliferator-activated receptor (PPAR) α , *J. Biol. Chem.* 291 (2016) 25179–25191.
- [28] J. Kapitulnik, M.D. Maines, Pleiotropic functions of biliverdin reductase: cellular signaling and generation of cytoprotective and cytotoxic bilirubin, *Trends Pharmacol. Sci.* 30 (2009) 129–137.
- [29] D.J. Fazakerley, R. Chaudhuri, P. Yang, G.J. Maghazal, K.C. Thomas, J.R. Krycer, S. J. Humphrey, et al., Mitochondrial CoQ deficiency is a common driver of mitochondrial oxidants and insulin resistance, *Elife* 7 (2018), e32111.
- [30] E.D. Abel, O. Peroni, J.K. Kim, Y.B. Kim, O. Boss, E. Hadro, T. Minnemann, et al., Adipose-selective targeting of the GLUT4 gene impairs insulin action in muscle and liver, *Nature* 409 (2001) 729–733.
- [31] S. Sugii, P. Olson, D.D. Sears, M. Saberi, A.R. Atkins, G.D. Barish, S.H. Hong, et al., PPAR γ activation in adipocytes is sufficient for systemic insulin sensitization, *Proc. Natl. Acad. Sci. U. S. A.* 106 (2009) 22504–22509.
- [32] M.J. Raher, H.B. Thibault, E.S. Buys, D. Kuruppu, N. Shimizu, A.L. Brownell, S. L. Blake, et al., A short duration of high-fat diet induces insulin resistance and predisposes to adverse left ventricular remodeling after pressure overload, *Am. J. Physiol. Heart Circ. Physiol.* 295 (2008) H2495–H2502.
- [33] K.P. Foley, S. Zliti, E. Denou, B.M. Duggan, R.W. Chan, J.C. Stearns, J. D. Schertzer, Long term but not short term exposure to obesity related microbiota promotes host insulin resistance, *Nat. Commun.* 9 (2018) 4681.
- [34] J.K. Lau, X. Zhang, J. Yu, Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances, *J. Pathol.* 241 (2017) 36–44.
- [35] C. Postic, J. Girard, Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice, *J. Clin. Invest.* 118 (2008) 829–838.
- [36] M. Morita, N. Ishida, K. Uchiyama, K. Yamaguchi, Y. Itoh, M. Shichiri, Y. Yoshida, et al., Fatty liver induced by free radicals and lipid peroxidation, *Free Radic. Res.* 46 (2012) 758–765.
- [37] V.W. Bowry, R. Stocker, Tocopherol-mediated peroxidation. The pro-oxidant effect of vitamin E on the radical-initiated oxidation of human low-density lipoprotein, *J. Am. Chem. Soc.* 115 (1993) 6029–6044.
- [38] R.A. Seidel, M. Kahnes, M. Bauer, G. Pohnert, Simultaneous determination of the bilirubin oxidation end products Z-BOX A and Z-BOX B in human serum using liquid chromatography coupled to tandem mass spectrometry, *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 974 (2015) 83–89.
- [39] K.R. Kranc, G.J. Pyne, L. Tao, T.D. Claridge, D.A. Harris, T.A. Cadoux-Hudson, J. J. Turnbull, et al., Oxidative degradation of bilirubin produces vasoactive compounds, *Eur. J. Biochem.* 267 (2000) 7094–7101.
- [40] R.J. Wanders, J. Komen, S. Kemp, Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans, *FEBS J.* 278 (2011) 182–194.
- [41] S. Xu, A. Jay, K. Brunaldi, N. Huang, J.A. Hamilton, CD36 enhances fatty acid uptake by increasing the rate of intracellular esterification but not transport across the plasma membrane, *Biochemistry* 52 (2013) 7254–7261.
- [42] A.F. McDonagh, Green jaundice revisited, *Am. J. Med.* 123 (2010) e23.

- [43] Y. Liu, P.R. Ortiz de Montellano, Reaction intermediates and single turnover rate constants for the oxidation of heme by human heme oxygenase-1, *J. Biol. Chem.* 275 (2000) 5297–5307.
- [44] J.D. Morrow, Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans, *Arterioscler. Thromb. Vasc. Biol.* 25 (2005) 279–286.
- [45] A.J. Sanyal, N. Chalasani, K.V. Kowdley, A. McCullough, A.M. Diehl, N.M. Bass, B. A. Neuschwander-Tetri, et al., Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, *N. Engl. J. Med.* 362 (2010) 1675–1685.
- [46] N. Chalasani, Z. Younossi, J.E. Lavine, M. Charlton, K. Cusi, M. Rinella, S. A. Harrison, et al., The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, *Hepatology* 67 (2018) 328–357.
- [47] N. Lerner-Marmarosh, T. Miralem, P.E. Gibbs, M.D. Maines, Human biliverdin reductase is an ERK activator; hBVR is an ERK nuclear transporter and is required for MAPK signaling, *Proc. Natl. Acad. Sci. U. S. A* 105 (2008) 6870–6875.
- [48] P.E. Gibbs, N. Lerner-Marmarosh, A. Poulin, E. Farah, M.D. Maines, Human biliverdin reductase-based peptides activate and inhibit glucose uptake through direct interaction with the kinase domain of insulin receptor, *Faseb. J.* 28 (2014) 2478–2491.
- [49] M. Haluzik, O. Gavrilo, D. LeRoith, Peroxisome proliferator-activated receptor- α deficiency does not alter insulin sensitivity in mice maintained on regular or high-fat diet: hyperinsulinemic-euglycemic clamp studies, *Endocrinology* 145 (2004) 1662–1667.
- [50] G. Marchesini, M. Brizi, G. Bianchi, S. Tomassetti, E. Bugianesi, M. Lenzi, A. J. McCullough, et al., Nonalcoholic fatty liver disease: a feature of the metabolic syndrome, *Diabetes* 50 (2001) 1844–1850.
- [51] M. Monetti, M.C. Levin, M.J. Watt, M.P. Sajjan, S. Marmor, B.K. Hubbard, R. D. Stevens, et al., Dissociation of hepatic steatosis and insulin resistance in mice overexpressing DGAT in the liver, *Cell Metabol.* 6 (2007) 69–78.
- [52] K. Minehira, S.G. Young, C.J. Villanueva, L. Yetukuri, M. Oresic, M.K. Hellerstein, R.V. Farese Jr., et al., Blocking VLDL secretion causes hepatic steatosis but does not affect peripheral lipid stores or insulin sensitivity in mice, *J. Lipid Res.* 49 (2008) 2038–2044.
- [53] A. Asai, P.M. Chou, H.F. Bu, X. Wang, M.S. Rao, A. Jiang, C.J. DiDonato, et al., Dissociation of hepatic insulin resistance from susceptibility of nonalcoholic fatty liver disease induced by a high-fat and high-carbohydrate diet in mice, *Am. J. Physiol. Gastrointest. Liver Physiol.* 306 (2014) G496–G504.
- [54] A. Amaro, E. Fabbrini, M. Kars, P. Yue, K. Schechtman, G. Schonfeld, S. Klein, Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia, *Gastroenterology* 139 (2010) 149–153.
- [55] D. Dekker, M.J. Dorresteijn, M. Pijnenburg, S. Heemskerk, A. Rasing-Hoogveld, D. M. Burger, F.A. Wagener, et al., The bilirubin-increasing drug atazanavir improves endothelial function in patients with type 2 diabetes mellitus, *Arterioscler. Thromb. Vasc. Biol.* 31 (2011) 458–463.
- [56] M. Li, W.W. Chan, S.D. Zucker, Association between atazanavir-induced hyperbilirubinemia and cardiovascular disease in patients infected with HIV, *J. Am. Heart Assoc.* 9 (2020), e016310.
- [57] E.R. Miller 3rd, R. Pastor-Barriuso, D. Dalal, R.A. Riemersma, L.J. Appel, E. Guallar, Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality, *Ann. Intern. Med.* 142 (2005) 37–46.
- [58] G. Bjelakovic, D. Nikolova, L.L. Gluud, R.G. Simonetti, C. Gluud, Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases, *Cochrane Database Syst. Rev.* (2012), CD007176.
- [59] E.A. Klein, I.M. Thompson Jr., C.M. Tangen, J.J. Crowley, M.S. Lucia, P. J. Goodman, L.M. Minasian, et al., Vitamin E and the risk of prostate cancer: the selenium and vitamin E cancer prevention trial (SELECT), *J. Am. Med. Assoc.* 306 (2011) 1549–1556.
- [60] M. Schürks, R.J. Glynn, P.M. Rist, C. Tzourio, T. Kurth, Effects of vitamin E on stroke subtypes: meta-analysis of randomised controlled trials, *Br. Med. J.* 341 (2010), c5702.